Gastrointestinal Stromal Tumors (GISTs) Clinical Trial
Official title:
Phase III Study of L-carnitine vs Placebo for the Treatment of Muscle Cramps After Imatinib in Patients With Gastrointestinal Stromal Tumors (GISTs) (Single-center Study)
we aim to evaluate the efficacy of L-carnitine for the treatment of muscle cramps after imatinib in patients with GIST and apply in the future.
One of the most common side effects of imatinib treatment, muscle cramps occur in about 30%
of patients with gastrointestinal stromal tumor (GIST) receiving treatment with imatinib.
It affects the quality of life (QoL) of patients and could also be a factor that affects
compliance with treatment. Some studies suggest that L-carnitine may improve muscle cramps
associated with cirrhosis or hemodialysis. However, the efficacy of L-carnitine for muscle
cramps occurring after imatinib treatment has yet to be reported. Thus, we aim to evaluate
the efficacy of L-carnitine for the treatment of muscle cramps after imatinib in patients
with GIST and apply in the future.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02889328 -
Phase II Study of Regorafenib Continuous Dosing of Regorafenib in Patients With GISTs
|
Phase 2 | |
| Completed |
NCT02712112 -
A Study of Intermittent Dosing Schedule of Imatinib in Patients With Tyrosine Kinase Inhibitor Refractory GISTs
|
Phase 2 | |
| Recruiting |
NCT01768104 -
ESTD vs. VATS for Upper Gastrointestinal Submucosal Tumors
|
N/A |